Laurus Labs Share Price Target: Laurus Labs, a major pharmaceutical has delivered a decent performance in the first quarter ended April-June 2026. The company’s profit rose 125 per cent, with its financial results exceeding market expectations and estimates.
Following the strong operational performance, improving profitability and positive business outlook, a brokerage firm has retained its Buy rating on the stock and set a new target price of Rs 1,820, indicating an estimated 14 per cent upside potential from the current market price.
Laurus Labs share price
Laurus Labs shares closed at Rs 1,602.30 last Friday, gaining Rs 34 or 2.17 per cent, as per the BSE. The stock had closed at Rs 1,568.30 in the previous session and opened at Rs 1,560 on Friday.
During the session, the stock touched a high of Rs 1,610, marking its 52-week all-time high. The stock’s 52-week low stands at Rs 810.75, while the company’s total market capitalisation is around Rs 86,500 crore.
Also Read | Investment Mantra: Why Warren Buffett and Charlie Munger call EBITDA a tool to mislead investors
Laurus Labs share price target
According to the brokerage report, considering the company’s strong financial results and positive future prospects, EBITDA estimates for FY2027 and FY2028 have been increased by 16 per cent to 18 per cent. Estimates for earnings per share (EPS) have also been raised by 21 per cent.
Laurus Labs’ medium-term outlook remains positive, supported by its expansion into new areas such as animal health and crop protection, along with continued investment in advanced infrastructure.
The brokerage said the company has increased its total capex for FY2027 to Rs 20,000 crore, compared with the earlier planned Rs 10,000 crore, to capitalise on strong global demand and new business opportunities.
Read More | Jamie Dimon Warns Investors: JPMorgan CEO explains why he isn’t buying stocks at current prices
Laurus Labs Q1 results
During the first quarter of the current financial year, the company’s consolidated revenue increased 29 per cent year-on-year to Rs 2,020 crore, significantly exceeding the market estimate of Rs 1,800 crore.
The growth was driven by the CDMO segment, which jumped 69 per cent to Rs 840 crore. The company also reported strong growth in profitability, with EBITDA rising 67 per cent to Rs 640 crore, while the EBITDA margin increased to 31.5 per cent.
The company’s profit rose 125 per cent to Rs 370 crore.
(Disclaimer: The above article is meant for informational purposes only and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)
